Immunogenic cell death in cancer and infectious disease L Galluzzi, A Buqué, O Kepp, L Zitvogel, G Kroemer Nature Reviews Immunology 17 (2), 97-111, 2017 | 2400 | 2017 |
Immunological effects of conventional chemotherapy and targeted anticancer agents L Galluzzi, A Buque, O Kepp, L Zitvogel, G Kroemer Cancer cell 28 (6), 690-714, 2015 | 1474 | 2015 |
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors L Galluzzi, J Humeau, A Buqué, L Zitvogel, G Kroemer Nature reviews Clinical oncology 17 (12), 725-741, 2020 | 879 | 2020 |
Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 840 | 2014 |
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 813 | 2020 |
Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 556 | 2014 |
Caloric restriction mimetics enhance anticancer immunosurveillance F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ... Cancer cell 30 (1), 147-160, 2016 | 504 | 2016 |
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy T Yamazaki, A Kirchmair, AI Sato, A Buqué, M Rybstein, G Petroni, N Bloy, ... Nature immunology 21 (10), 1160-1171, 2020 | 260 | 2020 |
Immunomodulation by targeted anticancer agents G Petroni, A Buqué, L Zitvogel, G Kroemer, L Galluzzi Cancer cell 39 (3), 310-345, 2021 | 159 | 2021 |
Trial Watch—Oncolytic viruses and cancer therapy J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ... Oncoimmunology 5 (2), e1117740, 2016 | 143 | 2016 |
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy K Iribarren, N Bloy, A Buqué, I Cremer, A Eggermont, WH Fridman, ... | 143 | 2015 |
Trial Watch: Peptide-based anticancer vaccines J Pol, N Bloy, A Buqué, A Eggermont, I Cremer, C Sautes-Fridman, ... Oncoimmunology 4 (4), e974411, 2015 | 142 | 2015 |
Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients ME Rodriguez-Ruiz, A Buqué, M Hensler, J Chen, N Bloy, G Petroni, ... Oncoimmunology 8 (11), e1655964, 2019 | 116 | 2019 |
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications A Buqué, N Bloy, F Aranda, F Castoldi, A Eggermont, I Cremer, ... Oncoimmunology 4 (4), e1008814, 2015 | 116 | 2015 |
eIF2α phosphorylation as a biomarker of immunogenic cell death O Kepp, M Semeraro, JM Bravo-San Pedro, N Bloy, A Buqué, X Huang, ... Seminars in cancer biology 33, 86-92, 2015 | 112 | 2015 |
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models T Yamazaki, A Buqué, TD Ames, L Galluzzi Oncoimmunology 9 (1), 1721810, 2020 | 97 | 2020 |
Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance N Bloy, P Garcia, CM Laumont, JM Pitt, A Sistigu, G Stoll, T Yamazaki, ... Immunological reviews 280 (1), 165-174, 2017 | 97 | 2017 |
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer A Buqué, N Bloy, M Perez-Lanzón, K Iribarren, J Humeau, JG Pol, ... Nature Communications 11 (1), 3819, 2020 | 84 | 2020 |
Trial Watch: Immunotherapy plus radiation therapy for oncological indications E Vacchelli, N Bloy, F Aranda, A Buqué, I Cremer, S Demaria, ... Oncoimmunology 5 (9), e1214790, 2016 | 81 | 2016 |
Modeling tumor immunology and immunotherapy in mice A Buqué, L Galluzzi Trends in Cancer 4 (9), 599-601, 2018 | 75 | 2018 |